TRACON Pharmaceuticals to Participate in Wells Fargo Securities 2019 Biotech Corporate Access Day

SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will participate in the Wells Fargo Securities 2019 Biotech Corporate Access Day on August 1, 2019 in San Francisco.
About TRACONTRACON develops targeted therapies for cancer and ophthalmic diseases. The Companya??s clinical-stage pipeline includes: DE-122, carotuximab being developed in wet AMD through a license to Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; TRC253, a small molecule being developed for the treatment of prostate cancer; and TJ004309, a CD73 antibody being developed for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it shares in the cost and risk of clinical development and commercialization of innovative product candidates.A  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.A  To learn more about TRACON and its product candidates, visit TRACON's website at

Company Contact:

Investor Contact:

Mark Wiggins

Andrew McDonald

Chief Business Officer

LifeSci Advisors LLC

(858) 251-3492

See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2020    »